{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:03:46Z","timestamp":1784963026750,"version":"3.55.0"},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.2169\/internalmedicine.1072-18","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T18:30:14Z","timestamp":1539714614000},"page":"703-705","source":"Crossref","is-referenced-by-count":20,"title":["A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis"],"prefix":"10.2169","volume":"58","author":[{"given":"Tamio","family":"Okimoto","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, National Cancer Center Research Institute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.","DOI":"10.1038\/nature05945"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25: 415-422, 2014.","DOI":"10.1093\/annonc\/mdt572"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29: e443-e445, 2011.","DOI":"10.1200\/JCO.2010.34.1313"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Metro G, Lunardi G, Floridi P, et al. CSF Concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 10: e26-e27, 2015.","DOI":"10.1097\/JTO.0000000000000468"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study. Lancet Oncol 15: 1119-1128, 2014.","DOI":"10.1016\/S1470-2045(14)70362-6"},{"key":"6","unstructured":"6. Xalkori interview form. 9th ed. Pfizer, Tokyo, 2017 (in Japanese)."},{"key":"7","unstructured":"7. Alecensa interview form. 7th ed. Chugai Pharmaceutical, Tokyo, 2017 (in Japanese)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74: 1023-1028, 2014.","DOI":"10.1007\/s00280-014-2578-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377: 829-838, 2017.","DOI":"10.1056\/NEJMoa1704795"},{"key":"10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"10. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390: 29-39, 2017.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-cancer Drugs 18: 23-28, 2007.","DOI":"10.1097\/01.cad.0000236313.50833.ee"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167-2177, 2014.","DOI":"10.1056\/NEJMoa1408440"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Katayama R, Sakashita T, Yanagitani N, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine 3: 54-66, 2016.","DOI":"10.1016\/j.ebiom.2015.12.009"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1072-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:34:02Z","timestamp":1551486842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1072-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1072-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}